Quality of life in patients (pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with the BCMA-DIRECTED CAR T cell therapy Idecabtagene Vicleucel (IDE-CEL, bb2121): Results from the KarMMa trial

被引：0
|
作者：
Weisel, K. [1 ]
Einsele, H. [2 ]
Goldschmidt, H. [3 ,4 ]
Delforge, M. [5 ]
San Miguel, J. [6 ]
Bertin, K. B. [7 ]
Tahir, M. [7 ]
Lewis, H. [8 ]
Wang, J. [9 ]
Braverman, J. [9 ]
Campbell, T. B. [9 ]
Munshi, N. [10 ,11 ,12 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] Univ Hosp Wurzburg, Wurzburg, Germany
[3] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany
[4] Univ Hosp Heidelberg, Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[5] Univ Hosp Leuven, Leuven, Belgium
[6] Univ Navarra Clin, Pamplona, Spain
[7] ICON Plc, San Francisco, CA USA
[8] ICON Plc, London, England
[9] Bristol Myers Squibb, Princeton, NJ USA
[10] Harvard Med Sch, Boston, MA 02115 USA
[11] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA
[12] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
214
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [1] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED KARMMA RESULTS
    Cavo, M.
    Oriol, A.
    San-Miguel, J.
    Kansagra, A.
    Madduri, D.
    Shah, N.
    Moreau, P.
    Yakoub-Agha, I.
    Delforge, M.
    Einsele, H.
    Goldschmidt, H.
    Weisel, K.
    Rambaldi, A.
    Reece, D.
    Rodriguez-Otero, P.
    Petrocca, F.
    Connarn, J.
    Patel, P.
    Huang, L.
    Campbell, T.
    Hege, K.
    Munshi, N.
    HAEMATOLOGICA, 2021, 106 (10) : 5 - 5
  • [2] Idecabtagene Vicleucel (ide-cel, bb2121), A BCMA-Directed Car T cell therapy, in patients with Relapsed and Refractory Multiple Myeloma (RRMM): Initial KarMMa results
    Einsele, H.
    Weisel, K.
    Goldschmidt, H.
    Munshi, N. C.
    Anderson, L. D., Jr.
    Shah, N.
    Jagannath, S.
    Berdeja, J.
    Lonial, S.
    Raje, N.
    Siegel, D. S.
    Lin, Y.
    Oriol, A.
    Moreau, P.
    Yakoub-Agha, I
    Delforge, M.
    Petrocca, F.
    Connarn, J. N.
    Patel, P.
    Huang, L.
    Campbell, T. B.
    Hege, K.
    San Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 90 - 91
  • [3] Idecabtagene vicleucel (ide-cel; bb2121); a BCMA-directed CAR T cell therapy; for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
    Einsele, Hermann
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus
    Lonial, Sagar
    Raje, Noopur
    Siegel, David S.
    Lin, Yi
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Goldschmidt, Hartmut
    Weisel, Katja
    Cavo, Michele
    Reece, Donna
    Rambaldi, Alessandro
    Truppel-Hartmann, Anna
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus
    Munshi, Nikhil C.
    Oriol, Albert
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 173 - 173
  • [4] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
    Anderson, Larry D., Jr.
    Munshi, Nikhil C.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Lin, Yi
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Petrocca, Fabio
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Results from the KarMMa clinical trial: Secondary Quality-of-Life domains in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with the BCMA-directed CAR T cell therapy Idecabtagene Vicleucel (ide-cel; bb2121)
    Einsele, H.
    Shah, N.
    Delforge, M.
    San-Miguel, J. F.
    Bertin, K. B.
    Tahir, M. J.
    Lewis, H. B.
    Wang, J.
    Braverman, J.
    Campbell, T. B.
    Dhanda, D.
    Munshi, N. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 206 - 208
  • [6] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur
    Siegel, David S.
    Lin, Yi
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Einsele, Hermann
    Goldschmidt, Hartmut
    Weisel, Katja
    Cavo, Michele
    Reece, Donna E.
    Rambaldi, Alessandro
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S17 - S18
  • [7] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-Cell therapy, in patients with relapsed and refractory multiple myeloma: Updated KarMMa results
    Einsele, H.
    Oriol, A.
    San-Miguel, J.
    Kansagra, A.
    Madduri, D.
    Shah, N.
    Moreau, P.
    Yakoub-Agha, I
    Delforge, M.
    Cavo, M.
    Goldschmidt, H.
    Weisel, K.
    Rambaldi, A.
    Reece, D.
    Rodriguez-Otero, P.
    Petrocca, F.
    Connarn, J. N.
    Patel, P.
    Huang, L.
    Campbell, T. B.
    Hege, K.
    Munshi, N. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 120 - 121
  • [8] Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial
    Shah, Nina
    Delforge, Michel
    San-Miguel, Jesus F.
    Bertin, Kaitlyn B.
    Tahir, Muna J.
    Lewis, Hannah B.
    Wang, Julie
    Braverman, Julia
    Campbell, Timothy B.
    Dhanda, Devender
    Munshi, Nikhil C.
    BLOOD, 2020, 136
  • [9] Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial
    Shah, Nina
    Munshi, Nikhil C.
    Berdeja, Jesus G.
    Jagannath, Sundar
    Finney, Olivia
    Martin, Nathan
    Agarwal, Amit
    Rowe, Everton
    Campbe, Timothy B.
    San-Miguel, Jesus F.
    BLOOD, 2021, 138
  • [10] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY: QUALITATIVE ANALYSES OF EARLY POST-TREATMENT INTERVIEWS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS IN THE KARMMA CLINICAL TRIAL
    Braverman, J.
    Dhanda, D. S.
    Moshkovich, O.
    Lanar, S.
    Miera, M.
    Williams, A. E.
    Murphy, R.
    Devlen, J.
    Hege, K.
    Campbell, T. B.
    VALUE IN HEALTH, 2021, 24 : S61 - S61
12345